Six-month treatment retention rates for people with opioid use disorder (OUD) were double for those who were treated with long-acting injected (LAI) naltrexone than for those who were treated with oral naltrexone. Treatment retention rates were 57.1% for those treated with a naltrexone LAI, compared to 28.1% who were treated with oral naltrexone.

These findings were reported in “A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder” by Maria A. Sullivan , M.D., Ph.D.; Adam Bisaga , M.D.; Martina Pavlicova , Ph . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

The News

Daily coverage of the developments shaping health and human services. From policy shifts to program innovations, reports on trends-shaping mental health, addiction treatment, child and family services, autism and I/DD, disability support and long-term care, social services, corrections, juvenile justice, chronic disease management, health care systems, and more-helping leaders make timely, informed decisions.

Filter Options

  • By Market
  • By Topic
  • By Date Range
  • Sort Date By
  • Results Per Page
Clear Filters